Menu
Search
|

Menu

Close
X

Arbutus Biopharma Corp ABUS.OQ (NASDAQ Stock Exchange Global Select Market)

5.25 USD
+0.00 (+0.00%)
As of Feb 23
chart
Previous Close 5.25
Open 5.25
Volume 24,590
3m Avg Volume 61,026
Today’s High 5.25
Today’s Low 5.05
52 Week High 8.25
52 Week Low 2.55
Shares Outstanding (mil) 55.03
Market Capitalization (mil) 493.14
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
21.99
5.77
Price to Book (MRQ)
vs sector
4.27
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-51.57
14.43
Return on Equity (TTM)
vs sector
-55.72
16.13

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100-8900 Glenlyon Pky
BURNABY   BC   V5J 5J8

Phone: +1604.4193200

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

SPONSORED STORIES